HOME ·

Clinical Trial

CSPC PHARMA (01093.HK): 8 trials to feature at ESMO 2026, two as LBAs
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-10-05
QYUNS-B (02509.HK): Oturkibart PN Phase III data at EADV 2026
Tags：
QYUNS-B02509.HKClinical Trial
2026-10-02
HENGRUI PHARMA (01276.HK): Two Drugs Win Clinical Trial Approval in China
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-09-22
CF PHARMTECH (02652.HK): ICF004 Phase I First Subject Dosed for ILD
Tags：
CF PHARMTECH02652.HKClinical Trial
2026-09-22
HENGRUI PHARMA (01276.HK): SHR-4595 Gets Clinical Trial Approval in China
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-09-22
CSPC PHARMA (01093.HK): SYH9102, World's First Ready-to-use Goserelin Extended-release Injection, Cleared for Clinical Trials in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-09
ALEBUND-B (09637.HK): FDA Clears IND for First-in-class IgA Protease AP308 in IgA Nephropathy; First-in-human Trial to Commence
Tags：
ALEBUND-B09637.HKClinical Trial
2026-09-08
CSPC PHARMA (01093.HK): Innovative Chemical Drug SYH2083 Eye Drops Obtains Clinical Trial Approval in China for Dry Eye Disease
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-08
CSPC PHARMA (01093.HK): Phase II clinical trial of SYH2085 tablets for uncomplicated influenza in adults officially initiated in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-07
HENGRUI PHARMA (01276.HK): Clinical trials approved for HRS-6209 capsules and HRS-4508 tablets in advanced breast cancer and solid tumors
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-09-07
HENGRUI PHARMA (01276.HK): HRS-1597 tablets approved for clinical trial for weight management
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-09-07
HENGRUI PHARMA (01276.HK): SHR-1179 injection approved for clinical trial, targeting weight management indication
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-09-07
LAEKNA-B (02105.HK): First subject enrolled in Phase I clinical study of LAE118 for advanced solid tumours
Tags：
LAEKNA-B02105.HKClinical Trial
2026-09-01
CSPC PHARMA (01093.HK): Phase I clinical trial of SYH2092 for weight management initiated in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-01
ABBISKO-B (02256.HK): First patient dosed in Phase I trial of pan-KRAS inhibitor ABSK211, preclinically covering multiple KRAS alterations
Tags：
ABBISKO-B02256.HKClinical Trial
2026-08-31
HUTCHMED (00013.HK): SANOVO Phase III of ORPATHYS plus TAGRISSO meets primary endpoint in first-line EGFR-mutant NSCLC, with significant PFS benefit
Tags：
HUTCHMED00013.HKClinical Trial
2026-08-31
ASCLETIS-B (01672.HK): First subject dosed in global Phase III program of oral GLP-1 agonist ASC30 for long-term weight management, targeting ~4,600 subjects
Tags：
ASCLETIS-B01672.HKClinical Trial
2026-08-30
CSPC PHARMA (01093.HK): Phase II Clinical Trial of SYH2069 Injection for Weight Management in Overweight or Obese Adults Launched at First Study Site in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-08-28
SBP GROUP (01177.HK): LM-364 "Nectin-4ᵀᴹᴱ ADC" Obtains Clinical Trial Approvals from NMPA and FDA, Accelerating Global Clinical Development
Tags：
SBP GROUP01177.HKClinical Trial
2026-08-28
IMMUNEONCO-B (01541.HK): First patient dosed in Phase II trial of IMM2510 plus IMM27M as first-line treatment for advanced HCC
Tags：
IMMUNEONCO-B01541.HKClinical Trial
2026-08-27
1234